Johnson&Johnson's MRI-safe indication for Cypher:
This article was originally published in Clinica
Executive Summary
Johnson & Johnson has received for its drug-eluting stent, Cypher, US FDA approval for MRI to be performed on patients immediately following the device's implantation. Cypher recipients typically had to wait for two months post device implantation before being scanned. Undergoing a scan sooner further enhances the overall level and quality of health care for stent patients, said the company. The FDA's decision comes just weeks after it granted a similar approval to Boston Scientific for its drug-eluting stent, Taxus.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.